These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33110117)

  • 1. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
    Cheng TY; Lee PC; Chen YT; Chao Y; Hou MC; Huang YH
    Sci Rep; 2020 Oct; 10(1):18375. PubMed ID: 33110117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
    Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
    Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis.
    Gu W; Tong Z
    J Int Med Res; 2020 Aug; 48(8):300060520946872. PubMed ID: 32815430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.
    Marasco G; Serenari M; Renzulli M; Alemanni LV; Rossini B; Pettinari I; Dajti E; Ravaioli F; Golfieri R; Cescon M; Festi D; Colecchia A
    J Gastroenterol; 2020 Oct; 55(10):927-943. PubMed ID: 32748172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.
    Sun R; Moraleda JM; Wei LJ
    JAMA Oncol; 2024 May; 10(5):674. PubMed ID: 38483380
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply.
    Qin S
    JAMA Oncol; 2024 May; 10(5):674-675. PubMed ID: 38483395
    [No Abstract]   [Full Text] [Related]  

  • 7. The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes.
    Cespiati A; Smith D; Lombardi R; Fracanzani AL
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Omega-3 Polyunsaturated Fatty Acids with Sarcopenia in Liver Cirrhosis Patients with Hepatocellular Carcinoma.
    Sano A; Inoue J; Kakazu E; Ninomiya M; Tsuruoka M; Sato K; Onuki M; Sawahashi S; Ouchi K; Masamune A
    J Clin Transl Hepatol; 2024 Jul; 12(7):613-624. PubMed ID: 38993515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
    Biselli M; Reggidori N; Iavarone M; Renzulli M; Lani L; Granito A; Piscaglia F; Lorenzini S; Alimenti E; Vara G; Caraceni P; Sangiovanni A; Marignani M; Gigante E; Brandi N; Gramenzi A; Trevisani F
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
    Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
    Ceballos MP; Angel A; Delprato CB; Livore VI; Ferretti AC; Lucci A; Comanzo CG; Alvarez ML; Quiroga AD; Mottino AD; Carrillo MC
    Eur J Pharmacol; 2021 Feb; 892():173736. PubMed ID: 33220273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
    Rizzo A; Mollica V; Massari F
    Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
    [No Abstract]   [Full Text] [Related]  

  • 14. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
    Dituri F; Scialpi R; Schmidt TA; Frusciante M; Mancarella S; Lupo LG; Villa E; Giannelli G
    Cell Death Dis; 2020 Nov; 11(11):984. PubMed ID: 33199679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study.
    Ding X; Sun W; Chen J; Li W; Shen Y; Guo X; Teng Y; Liu X; Sun S; Wei J; Li W; Chen H; Liu B
    Front Oncol; 2020; 10():578633. PubMed ID: 33194699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
    Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
    FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
    Anscher MS; Chang E; Gao X; Gong Y; Weinstock C; Bloomquist E; Adeniyi O; Charlab R; Zimmerman S; Serlemitsos-Day M; Ning YM; Mayrosh R; Fuller B; Trentacosti AM; Gallagher P; Bijwaard K; Philip R; Ghosh S; Fahnbulleh F; Diggs F; Arora S; Goldberg KB; Tang S; Amiri-Kordestani L; Pazdur R; Ibrahim A; Beaver JA
    Oncologist; 2021 Feb; 26(2):139-146. PubMed ID: 33145877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
    Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
    Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.